Profile your compound using clinical endpoints
Explore Gubra’s spirometry-confirmed BLEO-IPF mouse models
Gubra offers advanced bleomycin-induced and spirometry-confirmed mouse models of Idiopathic Pulmonary Fibrosis (IPF). The combination of lung function and respiratory capacity testing and an automated AI-based histopathology pipeline enables objective and accurate analysis of drug effects.
American Thoracic Society (ATS) 2024
Download our posters
Discover how we can advance your drug development with our preclinical bleomycin-induced mouse models with hallmarks of lung dysfunction confirmed using spirometry and whole body plethysmography.
Standard Study Outlines
Cloud-based brain data viewer
Get Actionable Data in GubraView
Our cloud-based data viewer GubraView provides instant access to study data as it is uploaded, ensuring seamless monitoring throughout your study. With features for cross-group and cross-study comparisons, GubraView enables informed decision-making with statistical analyses. Accessible across multiple locations, GubraView empowers efficient and collaborative drug development for your whole team.
“
We are experts in bridging preclinical and clinical development.
MICHAEL FEIGH Vice President, Scientific Sales
Michael’s primary focus is on metabolic dysfunction-associated steatohepatitis (MASH), obesity and idiopathic pulmonary fibrosis (IPF). Michael help customers with his scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.
Let’s meet at the EASL 2023
Contact us
Gubra
Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650